Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Bo Kruse Biography and Net Worth

CFO of Y-mAbs Therapeutics

Bo Kruse serves as Chief Financial Officer, Treasurer, and Secretary of the Company. Mr. Kruse has broad international finance experience, including knowledge of capital markets, accounting, and other financing activities. Prior to joining the Company, Mr. Kruse was the Chief Financial Officer of the Danish biotech company Azanta A/S from 2009 to 2015. Further, Mr. Kruse served as Genmab A/S’ Vice President and Chief Financial Officer from 2005 to 2008, and in a number of other finance positions, including Vice President and Chief Accounting Officer, from 2000 to 2005. During his eight-year tenure at Genmab, Mr. Kruse was directly involved in several financing rounds, including Genmab’s initial public offering. Mr. Kruse has a Master’s and Bachelor of Science in Commerce degree from Copenhagen Business School, Denmark.

What is Bo Kruse's net worth?: The estimated net worth of Bo Kruse is at least $1.75 million as of May 31st, 2024. Mr. Kruse owns 210,877 shares of Y-mAbs Therapeutics stock worth more than $1,746,062 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Kruse may own. Additionally, Mr. Kruse receives an annual salary of $685,020.00 as CFO at Y-mAbs Therapeutics. Learn More about Bo Kruse's net worth.
How old is Bo Kruse?: Mr. Kruse is currently 51 years old. There are 7 older executives and no younger executives at Y-mAbs Therapeutics. The oldest executive at Y-mAbs Therapeutics is Dr. Torben Lund-Hansen M.Sc., Ph.D., Senior VP & CTO, who is 73 years old. Learn More on Bo Kruse's age.
What is Bo Kruse's salary?: As the CFO of Y-mAbs Therapeutics, Inc., Mr. Kruse earns $685,020.00 per year. There are 2 executives that earn more than Mr. Kruse. The highest earning executive at Y-mAbs Therapeutics is Mr. Thomas Gad, Founder, Chief Business Officer & Vice Chairman, who commands a salary of $1,050,000.00 per year. Learn More on Bo Kruse's salary.
How do I contact Bo Kruse?: The corporate mailing address for Mr. Kruse and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at [email protected]. Learn More on Bo Kruse's contact information.
Has Bo Kruse been buying or selling shares of Y-mAbs Therapeutics?: Bo Kruse has not been actively trading shares of Y-mAbs Therapeutics during the last quarter. Most recently, Bo Kruse sold 31,371 shares of the business's stock in a transaction on Friday, May 31st. The shares were sold at an average price of $12.07, for a transaction totalling $378,647.97. Following the completion of the sale, the chief financial officer now directly owns 210,877 shares of the company's stock, valued at $2,545,285.39. Learn More on Bo Kruse's trading history.
Who are Y-mAbs Therapeutics' active insiders?: Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), and Johan Wedell-Wedellsborg (Director). Learn More on Y-mAbs Therapeutics' active insiders.
Are insiders buying or selling shares of Y-mAbs Therapeutics?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 201,155 shares worth more than $2,570,307.80. The most recent insider tranaction occured on September, 16th when insider Thomas Gad sold 30,000 shares worth more than $389,100.00. Insiders at Y-mAbs Therapeutics own 22.5% of the company. Learn More about insider trades at Y-mAbs Therapeutics.
Information on this page was last updated on 9/16/2024.

Bo Kruse Insider Trading History at Y-mAbs Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2024	Sell	31,371	$12.07	$378,647.97	210,877
2/22/2022	Sell	4,000	$7.85	$31,400.00
2/4/2022	Sell	4,000	$7.97	$31,880.00
1/24/2022	Sell	4,000	$9.84	$39,360.00
1/4/2022	Sell	4,000	$17.12	$68,480.00
12/22/2021	Sell	4,000	$16.36	$65,440.00
12/6/2021	Sell	4,000	$16.35	$65,400.00
11/22/2021	Sell	4,000	$18.09	$72,360.00
10/22/2021	Sell	4,000	$25.94	$103,760.00
10/4/2021	Sell	4,000	$28.78	$115,120.00
9/22/2021	Sell	4,000	$30.82	$123,280.00
9/7/2021	Sell	4,000	$32.03	$128,120.00	225,077
8/23/2021	Sell	4,000	$28.60	$114,400.00
8/4/2021	Sell	4,000	$33.72	$134,880.00
7/22/2021	Sell	4,000	$34.50	$138,000.00
7/22/2021	Sell	4,000	$34.50	$138,000.00
7/6/2021	Sell	4,000	$34.15	$136,600.00
6/22/2021	Sell	4,000	$36.17	$144,680.00	245,077
6/4/2021	Sell	4,000	$33.48	$133,920.00	249,077
5/24/2021	Sell	4,000	$35.61	$142,440.00	253,077
5/13/2020	Sell	14,724	$37.86	$557,450.64	285,276

Bo Kruse Buying and Selling Activity at Y-mAbs Therapeutics

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Today's Range

Now: $8.28

$8.00

$8.50

50 Day Range

MA: $12.36

$8.28

$15.69

2 Week Range

Now: $8.28

$6.10

$20.90

Volume

1,143,018 shs

Average Volume

328,133 shs

Market Capitalization

$370.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Missed Nvidia? Buy Elon Musk’s “Silent Partner”

From Brownstone Research | Ad

So please click here to see the details because a lot of people could get rich.

Bo Kruse Biography and Net Worth

What is Bo Kruse's net worth?

How old is Bo Kruse?

What is Bo Kruse's salary?

How do I contact Bo Kruse?

Has Bo Kruse been buying or selling shares of Y-mAbs Therapeutics?

Who are Y-mAbs Therapeutics' active insiders?

Are insiders buying or selling shares of Y-mAbs Therapeutics?